A common heart failure medication can lock HIV inside immune cells and prevent the virus from waking up.
April 23, 2026
Original Paper
Levosimendan inhibits HIV-1 infection in myeloid cells in the RIOK1-dependent manner
SSRN · 6573144
The Takeaway
Levosimendan works by targeting a specific protein in myeloid cells, which are the primary hidden reservoirs for the virus. While current treatments keep the virus at bay, they cannot stop it from reactivating if the medication is paused. This heart drug successfully inhibits both infection and reactivation in the very cells where HIV hides most effectively. It offers a potential path to a permanent functional cure by turning off the viral on switch.
From the abstract
Despite of the highly potent antiretroviral therapies, HIV-1 establishes persistent infection and causes chronic inflammation in AIDS patients. Beyond CD4+ T cells, HIV-1 infects myeloid cells, including circulating monocytes and tissue-resident macrophages, and integrates with host genomes to form stable viral reservoirs. To achieve a functional HIV cure, latency-promoting agents (LPAs) have been developed for the "block-and-lock" strategy to reinforce deep HIV-1 latency and permanently silence